Enovis (NYSE:ENOV) Updates FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 3.520-3.730 for the period, compared to the consensus earnings per share estimate of 3.540. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Analyst Upgrades and Downgrades

ENOV has been the subject of several research analyst reports. BMO Capital Markets assumed coverage on shares of Enovis in a research report on Wednesday, July 8th. They set an “outperform” rating and a $29.00 target price for the company. Wells Fargo & Company cut their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Enovis in a report on Friday, May 22nd. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Finally, William Blair began coverage on shares of Enovis in a report on Friday, April 17th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Enovis currently has a consensus rating of “Moderate Buy” and an average price target of $41.86.

Enovis Trading Down 2.6%

Shares of ENOV opened at $30.07 on Thursday. The company’s fifty day moving average is $24.47 and its 200 day moving average is $23.93. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock has a market capitalization of $1.73 billion, a PE ratio of -1.51 and a beta of 1.34. Enovis has a fifty-two week low of $19.14 and a fifty-two week high of $34.28.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. The business had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis will post 3.12 earnings per share for the current fiscal year.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have bought 4,200 shares of company stock worth $92,084. 2.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enovis

A number of large investors have recently bought and sold shares of ENOV. AQR Capital Management LLC boosted its stake in shares of Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. increased its position in Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after purchasing an additional 73,116 shares during the period. Empowered Funds LLC lifted its stake in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares in the last quarter. Finally, Amundi increased its holdings in shares of Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.